Commentary
Podcast
Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease
Author(s):
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joel Salinas, MD, MBA. [LISTEN TIME: 10 minutes]
Joel Salinas, MD, MBA
A special episode of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.
This episode, "FDA Approves Donanemab for Early Symptomatic Alzheimer Disease," features an exclusive interview with Joel Salinas, MD, MBA, a behavioral neurologist at NYU Langone, to discuss the impacts of the approval. Salinas, who also serves as the chief medical officer at Isaac Health, gave insight on the considerations and caution with prescribing donanemab, including the importance of identifying whether patient's are a true candidate for treatment. In addition, he spoke on the education and awareness around these new novel treatments for AD, and some of the next steps in continuing momentum in the field going forward.1
For more of NeurologyLive's coverage of donanemab's approval, head here: FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease
EPISODE BREAKDOWN
- 2:10 – Positive downstream impacts of donanemab's approval
- 4:20 – Considerations and caution with prescribing donanemab
- 6:05 – Salinas on patient-clinician conversations about AD treatments
- 8:00 – Closing remarks and continued progress in AD field
Click here to subscribe to the Mind Moments® podcast. Be sure to leave a rating and review for the show. Thanks for listening!
